Company Amount Raised Auris Medical AG $50.8M Jounce Therapeutics Inc. $47M Opsona Therapeutics Ltd. $43.2M Radius Health Inc. $43M GenSight Biologics $41.6M Esperion Therapeutics Inc. $33M Revance Therapeutics Inc. $33M Syros Pharmaceuticals $30M Labrys Biologics Inc. $31M Versartis Inc. $25M

I. COMMENCED TRADING IN APRIL Company (Symbol)# Date Filed Date Comm. Shares/ Units (M) Price Shares Out (M)@ Lead, Other Underwriters Gross (US$M) Post- Offering Market Cap (M)% INITIAL OFFERINGS Chimerix Inc. (Research Triangle Park, N.C.; CMRX)1 3/8/13 4/11/13 7.32S $14 24.4 Morgan Stanley Cowen & Co. (co-lead) William Blair Lazard Capital Markets $102.5 $341.6 Omthera Pharmaceuticals Inc. (Princeton, N.J.; OMTH)2 3/8/13 4/12/13 8S $8 24.4 BofA Merrill Lynch Barclays (co-lead

"There are very good early stage venture capitalists. But, as the pathway to approval under the FDA becomes longer and more expensive, it requires either a significant amount of long-term-view strategic focus to get through that pathway, or a significant amount of capital or both." – Luke Düster, principal with Capital Royalty L.P., on the closing of the firm's second fund "Phase I is a great time to buy if you're a pharma company. I think there's a lot of motivation for sellers to go as far as

Total: $416.95M Company Location Amt. (M) Details Date ActoGeniX NV Ghent, Belgium €10.7 ($14) ActoGeniX closed a Series B round, raising $14M, led by Saffelberg Investment, with the company's founders and GIMV, Biotech Fund Flanders, Baekeland Fund, BioVest CVA, Life Sciences Partners, Aescap Ventures and Ventech 4/19/13 Allecra Therapeutics GmbH Lorrach, Germany €15 ($19.6) Allecra raised $19.6M in a Series A round from Edmond de Rothschild Investment Partners, Forbion Capital Partners and

A report from real estate firm Jones Lang LaSalle in March lists San Diego as the number two biotechnology cluster in the U.S. Like any list, the ranking is debatable, especially by people in the San Francisco Bay Area who came in third. But whether the region is ranked first, second, or third, it's pretty clear San Diego and the rest of Southern California is an important region for the biotech industry. At the helm, serving as a guiding force, is Biocom, the 25-year old, including predecessors

By taking a detailed look at toxicities of a bispecific antibody that targets the transferrin receptor to cross the blood-brain-barrier, researchers at Genentech Inc. have gained new insights into both "important safety concerns and potential mitigation strategies" for the therapeutic development of such antibodies. The current studies, which were published in the May 2, 2013, issue of Science Translational Medicine, came out of work published in 2011 describing an antibody with two binding

Company Amount Raised Ironwood Pharmaceuticals Inc. $175M OPKO Health Inc. $175M Mesoblast Ltd. $174.6M Pacira Pharmaceuticals Inc. $110M e-Therapeutics plc $62.66M

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 13-1 against the adequacy of AVEO Oncology Inc.'s single Phase III trial to support the approval of tivozanib.

Total: $85.5M Year to Date: $204.55M Company (Location) Partner (Location) Amt. (M) Details Date Arena Pharmaceuticals Inc. (San Diego) Eisai Inc. (Woodcliff Lake, N.J.) $0.5 For the submission of a marketing authorization application for Belviq in Mexico for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults 4/2/13 Furiex Pharmaceuticals Inc. (Morrisville, N.C.) Menarini Group (Florence, Italy) $5 For the launch of Priligy in

"I think every client I've ever had has tried to think of ways to extend the monopoly they've enjoyed." – Edmund Pitcher, patent attorney "There is no reason, I think, [for biotechs] to feel threatened as assets tend to spend the 'internship' years with biotechs. Great things graduate from academic institutions, but new graduates are seldom ready for real life." – Jeff Stewart, director of Raleigh, N.C.-based biopharma consultant Campbell Alliance, discussing the trend toward partnering

CHICAGO – It was certainly an interesting week for Canada's biotechnology industry, with two big pharmas using the BIO 2013 International Convention to make announcements about their investments in the nation's research and development. Merck Canada Inc., of Kirkland, Quebec, revealed that it will be providing C$4 million (US$3.9 million) through two collaborative partnerships. Thomas Cannell, president and managing director of Merck Canada, said the first is an investment in a public-private

Financing Anterios Inc. closed an $8.5 million corporate financing. Esperion Therapeutics Inc. pulled down $33 million in a preferred stock financing. Genticel SA raised $23.6 million in a Series C round led by Wellington Partners. GW Pharmaceuticals plc set the terms for its proposed U.S. IPO aiming to raise about $40 million. iBio Inc. priced a public offering of 8.925 million units at 48 cents each, raising $4.28 million. Insys Therapeutics Inc. plans to raise $68 million in an IPO of 4

Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date FEBRUARY Exelixis Inc. (South San Francisco) Swedish Orphan Biovitrum AB (Stockholm, Sweden) ND Partnership to distribute and commercialize Cometriq (cabozantinib) for metastatic medullary thyroid cancer in the European Union and potentially other countries The agreement will last for three years, with Exelixis maintaining full commercial rights outside the covered territory and for all other indications 2/25

Company Company Deal Value Biogen Idec Inc. Elan Corp. plc $3.25B MacroGenics Inc. Gilead Sciences Inc. $1B bluebird bio Celgene Corp. $225M The Medicines Co. Alnylam Pharmaceuticals Inc. $205M Afraxis Inc. Genentech Inc. $187.5M BIND Biosciences Inc. Amgen Inc. $180.5M Concert Pharmaceuticals Inc. Jazz Pharmaceuticals plc $120M Genentech Inc. RQx Pharmaceuticals Inc. $111M